comprehensive -WSS

comprehensive

author：fashion 2025-10-02 05:38:24 - browse：94846

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： People with mental disorders often marry others with same

focus

hotspot

WSS

Overprescribed: High cost isn't America's only drug problem

Covid silver lining: Unprecedented look at human immune system

Keeping primary care docs in field isn't impossible, says AAFP CEO

Young boy dies in trial for Pfizer Duchenne gene therapy

HCA sued by state AG for quality issues at Mission Health

Mass General Brigham physicians react to latest merger step

Wikipedia

comprehensive

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Jerome Adams on the need for new antivirals for Covid

Study: Black kids more likely to die after surgery than white kids

Virginia high school admissions case could be legal follow

Insurer loopholes limit power of law against surprise medical bills

说起来，杜蕾斯的广告文案是相当值得学习的：《可能是最污的顶尖创意，杜蕾斯2016年微博文案盘点》　　2、用视觉呈现故事　　　　故事可以成为一个广告的优质载体。

Trial using CRISPR to edit HIV out of cells disappoints

ChatGPT in medicine: STAT answers readers' burning questions

In Spain, a hospital brews its own CAR

focus

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Readout Newsletter: The latest on Moderna, Apellis, and Merck

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Can sheer will power keep patients alive in their dying hours?

U.K. decision on ALS drug has neurologists, advocates up in arms

Scientific mystery highlights the blind spots in genomics databases

focus

knowledge

hotspot

Wikipedia